- Q1 2024 Calliditas Therapeutics AB Earnings Call TranscriptMay 23, 2024kr122.2 (+7.19%)Earnings
- Q4 2023 Calliditas Therapeutics AB Earnings Call TranscriptFeb 21, 2024kr108.3 (+1.31%)Earnings
- Q3 2023 Calliditas Therapeutics AB Earnings Call TranscriptNov 07, 2023kr87.6 (-5.40%)Earnings
- Q2 2023 Calliditas Therapeutics AB Earnings Call TranscriptAug 17, 2023kr86.25 (-13.92%)Earnings
- Q1 2023 Calliditas Therapeutics AB Earnings Call TranscriptMay 16, 2023kr107.2 (-18.42%)Earnings
- Calliditas Therapeutics AB Nefigard Topline Data Presentation TranscriptMar 13, 2023
- Q4 2022 Calliditas Therapeutics AB Earnings Call TranscriptFeb 23, 2023kr107 (+16.49%)Earnings
- Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd TranscriptDec 14, 2022
- Q3 2022 Calliditas Therapeutics AB Earnings Call TranscriptNov 14, 2022kr78.9 (+0.96%)Earnings
- Calliditas Therapeutics AB KOL Webinar TranscriptNov 08, 2022
- Q2 2022 Calliditas Therapeutics AB Earnings Call TranscriptAug 18, 2022kr91.8 (-15.55%)Earnings
- Q1 2022 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2022kr79.6 (+7.49%)Earnings
- Q4 2021 Calliditas Therapeutics AB Earnings Call TranscriptFeb 24, 2022kr81.3 (-6.12%)Earnings
- Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy TranscriptDec 16, 2021
- Q3 2021 Calliditas Therapeutics AB Earnings Call TranscriptNov 18, 2021kr80 (+8.25%)Earnings
- Q2 2021 Calliditas Therapeutics AB Earnings Call TranscriptAug 19, 2021kr96.5 (-1.63%)Earnings
- Q1 2021 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2021kr120.8 (+0.50%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptMar 10, 2021
- Q4 2020 Calliditas Therapeutics AB Earnings Call TranscriptFeb 18, 2021kr128.6 (-3.02%)Earnings
- Calliditas Therapeutics AB Corporate Analyst Meeting TranscriptJan 20, 2021
- Q3 2020 Calliditas Therapeutics AB Earnings Call TranscriptNov 12, 2020kr145.8 (-4.58%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptNov 09, 2020
- Q2 2020 Calliditas Therapeutics AB Earnings Call TranscriptAug 13, 2020kr103 (+2.39%)Earnings
- Q1 2020 Calliditas Therapeutics AB Earnings Call TranscriptMay 14, 2020kr92.5 (-9.49%)Earnings
Q1 2021 Calliditas Therapeutics AB Earnings Call Transcript
Ladies and gentlemen, welcome to the Calliditas Therapeutics Q1 2021 Conference. (Operator Instructions)
I'll now hand the floor to CEO, Renee Lucander. Please begin your meeting.
()-
Thank you, and welcome to this Q1 2021 report from Calliditas. If you turn to Page 2, and before we begin, giving our listing on NASDAQ Global Select, I would just like to draw your attention to the forward-looking statements.
So turning to Page 3. In Q1, the company reached a major milestone with a filing for approval in IgA nephropathy with the FDA. This is the first-ever submission for proven IgAN, and it provides for thousands of patients living every day with this progressive disease. We subsequently received priority review from the FDA, and we're also granted accelerated assessment by EMA in April.
We continue to deliver on our plan, and we will submit our dossier to EMA this quarter, as previously announced, and we're very excited to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)